JW Therapeutics

OverviewSuggest Edit

JW Therapeutics is a biotech company focusing on clinical cell therapy technology. The Company is aimed to develop, transform and promote breakthrough cell-based immunotherapies to fight against cancer.

TypePrivate
Founded2016
HQCN
Websitejwtherapeutics.com

Latest Updates

Employees (est.) (Aug 2022)96
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at JW Therapeutics

Harry Lam

Harry Lam

Chief Technology Officer and Senior Advisor
Xin Fu

Xin Fu

Senior Vice President and Chief Finance Officer
Shaun Paul Cordoba

Shaun Paul Cordoba

Senior Vice President and Chief Scientific Officer
Alex Wu

Alex Wu

Senior Vice President and Chief Commercial Officer
James Li

James Li

Co-founder, Chairman and Chief Executive Officer
Raymond J. Hage

Raymond J. Hage

Senior Vice President, Corporate Development
Show more

JW Therapeutics Office Locations

JW Therapeutics has an office in Suzhou Shi
Suzhou Shi, CN
Sang Tian Jie, Wuzhong Qu
Show all (4)

JW Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2016

JW Therapeutics total Funding

$90 m

JW Therapeutics latest funding size

$90 m

Time since last funding

4 years ago

JW Therapeutics investors

JW Therapeutics's latest funding round in March 2018 was reported to be $90 m. In total, JW Therapeutics has raised $90 m
Show all financial metrics

JW Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Syracuse BiopharmaJuly 26, 2020

JW Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

JW Therapeutics Online and Social Media Presence

Embed Graph

JW Therapeutics News and Updates

JW Therapeutics Announces Initiation of Clinical Study of JWATM204 in Patients with Advanced Hepatocellular Carcinoma

SHANGHAI, July 4, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the initiation of phase I clinical study of JWATM204 in patients with...

JW Therapeutics Presents Latest Data of Carteyva® at 2022 ASCO Annual Meeting

SHANGHAI, June 5, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, presented the latest data of three clinical studies on Carteyva® (relmacabtagene...

JW Therapeutics to Present Latest Data of Carteyva® at 2022 ASCO Annual Meeting

SHANGHAI, May 8, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that it will present the latest clinical study data for Carteyva® via...

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in Mantle Cell Lymphoma in China

SHANGHAI, April 3, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the Center for Drug Evaluation (CDE) of the National Medical Products...

JW Therapeutics Announces NMPA Acceptance of the Supplemental New Drug Application for Carteyva® in Patients with Relapsed or Refractory Follicular Lymphoma

SHANGHAI, Feb. 27, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) of China accepted...

JW Therapeutics Announces Two Appointments to Strengthen R&D Capability and Pipeline Building

SHANGHAI, Jan. 9, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, recently announced the appointments of Dr. Shaun Paul Cordoba as Chief Scientific...
Show more

JW Therapeutics Frequently Asked Questions

  • When was JW Therapeutics founded?

    JW Therapeutics was founded in 2016.

  • Who are JW Therapeutics key executives?

    JW Therapeutics's key executives are Harry Lam, Xin Fu and Shaun Paul Cordoba.

  • How many employees does JW Therapeutics have?

    JW Therapeutics has 96 employees.

  • Who are JW Therapeutics competitors?

    Competitors of JW Therapeutics include Neovii, Eutilex and Foghorn Therapeutics.

  • Where are JW Therapeutics offices?

    JW Therapeutics has an office in Suzhou Shi.

  • How many offices does JW Therapeutics have?

    JW Therapeutics has 4 offices.